Skip to content

Studying DNA in Tumor Tissue Samples From Patients With Localized or Metastatic Osteosarcoma

Genomic Study of Metastatic Osteosarcoma Using Next-Generation Sequencing Technology

Status
Completed
Phases
Unknown
Study type
Observational
Source
ClinicalTrials.gov
Registry ID
NCT01062438
Enrollment
99
Registered
2010-02-04
Start date
2010-01-31
Completion date
2011-09-30
Last updated
2015-05-06

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Sarcoma

Keywords

localized osteosarcoma, metastatic osteosarcoma

Brief summary

RATIONALE: Studying samples of tumor tissue and blood from patients with cancer in the laboratory may help doctors learn more about changes that occur in DNA and identify biomarkers related to cancer. PURPOSE: This research study is looking at DNA in tumor tissue samples from patients with localized or metastatic osteosarcoma.

Detailed description

OBJECTIVES: * Determine the genomic expression profile in tumor tissue samples from patients with localized or metastatic osteosarcoma using transcriptome sequencing. * Identify activating and loss of function mutations and gene rearrangement in these tumor tissue samples using transcriptome sequencing. * Identify candidate genes that are important in osteosarcoma and tumorigenesis using genome partition strategies for genomic DNA sequencing. * Identify which mutations are associated with outcome. * Establish which mutations are also found in germ line DNA that predispose the patient to osteosarcoma. OUTLINE: DNA and RNA from banked tumor tissue samples and DNA from paired blood samples are analyzed in sequencing studies using next-generation sequencing technology. The sequencing data from these tumor samples are matched to the Human RefSeq (for transcriptome sequencing) and normal human genome in the public databases and to the patient's germ line sequence to identify constitutional and somatic mutations. Clinical information that is associated with each sample (i.e., age, tumor site, size, primary metastases, response to chemotherapy, surgical remission, follow-up time, and treatment protocol) is also collected, if available.

Interventions

GENETICDNA analysis
GENETICRNA analysis
GENETICgene expression analysis
GENETICmutation analysis
OTHERlaboratory biomarker analysis

Sponsors

National Cancer Institute (NCI)
CollaboratorNIH
Children's Oncology Group
Lead SponsorNETWORK

Study design

Observational model
COHORT
Time perspective
RETROSPECTIVE

Eligibility

Sex/Gender
ALL
Healthy volunteers
No

Inclusion criteria

DISEASE CHARACTERISTICS: * Diagnosis of localized or metastatic osteosarcoma * Banked snap-frozen tumor tissue samples and paired blood DNA samples available PATIENT CHARACTERISTICS: * Not specified PRIOR CONCURRENT THERAPY: * Not specified

Design outcomes

Primary

MeasureTime frame
Genomic expression profile in osteosarcoma tumor samples using transcriptome sequencing
Identification of activating and loss of function mutations and gene rearrangement using transcriptome sequencing
Mutations associated with outcome
Mutations also found in germ line DNA that predispose the patient to osteosarcoma

Outcome results

None listed

Source: ClinicalTrials.gov · Data processed: Feb 4, 2026